Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

2015

Background Efficacy and safety data for combining bevacizumab, gemcitabine, and paclitaxel for locally advanced/metastatic breast cancer are limited.

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

23

References

10

Citations